|
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
However, overexpression of G-CSF has been implicated in several important processes in tumor biology such as tumor growth, angiogenesis, and metastasis.
|
31522450 |
2019 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
We conclude that, whilst the evidence for a promotion of metastasis is strong in preclinical models and that limited data indicate that high serum G-CSF levels in patients are associated with poorer prognosis, no studies published so far have revealed evidence of increased tumour progression associated with supportive G-CSF use during chemotherapy in patients.
|
29968171 |
2018 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
As a high neutrophil-to-lymphocyte ratio in patients predicts poor outcome, while mild neutropenia predicts an improved outcome, we urge caution in the use of G-CSF in neutrophil recovery following chemotherapy as there is increasing evidence in preclinical models that G-CSF can promote metastasis.
|
28834401 |
2018 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
However, in a previous meta-analysis, G-CSF prophylaxis was associated with an increased risk of secondary malignancies while reducing long-term mortality.
|
30099478 |
2018 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
<i>In vitro</i> and <i>in vivo</i> investigations revealed that MDSCs produced in response to tumor-derived G-CSF are involved in premetastatic niche formation, which promotes visceral organ metastasis of TRL-positive cancer.
|
29752277 |
2018 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Upregulation of microRNA-125b by G-CSF promotes metastasis in colorectal cancer.
|
28881590 |
2017 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
It has been shown that Granulocyte colony-stimulating factor (G-CSF) has a higher expression in malignant tumors, and anti-G-CSF therapy considerably decreases tumor growth, tumor vascularization and metastasis.
|
28646705 |
2017 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
The levels of spontaneous production of interleukin (IL)-10 and granulocyte colony-stimulating factor (G-CSF) and the amounts of IL-2, IL-10, G-CSF and monocyte chemoattractant protein-1 (MCP-1) produced during stimulation by PAs, as well as the index of stimulation by polyclonal activators (ISPA) for IL-2 production, were lower for MAC with LN metastasis than for MAC without LN metastasis.
|
28745079 |
2017 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Circulating concentrations of the cytokines interleukin-6 (IL-6), granulocyte colony-stimulating factor (G-CSF) and chemokines monocyte chemotatic protein 1 (MCP-1)/CCL2 and growth-regulator oncogene α (GROα)/chemokine C-X-C motif ligand 1 are commonly increased in cancer patients and they are increasingly recognised as important promoters, via divergent mechanisms, of cancer progression and metastasis.
|
24384681 |
2014 |
|
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
Thus, we advance the hypothesis that G-CSF expression is serving as a marker of a more generalized trans-dominant pathway linked to tumor progression and metastasis.
|
9060833 |
1997 |
|
Neoplasm Metastasis
|
0.400 |
Therapeutic
|
phenotype |
CTD_human |
Neurobiochemical changes from Taxol/Neupogen chemotherapy for metastatic breast carcinoma corresponds with suicidal depression.
|
9018096 |
1996 |
|
Neoplasm Metastasis
|
0.400 |
Therapeutic
|
phenotype |
CTD_human |
High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: a European Cancer Center trial.
|
7543699 |
1995 |